Jefferies Financial Group Inc. Acquires New Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Jefferies Financial Group Inc. purchased a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 185,000 shares of the company's stock, valued at approximately $5,076,000. Jefferies Financial Group Inc. owned about 0.10% of BridgeBio Pharma at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of BBIO. Ironwood Investment Management LLC boosted its position in shares of BridgeBio Pharma by 0.5% during the fourth quarter. Ironwood Investment Management LLC now owns 63,157 shares of the company's stock worth $1,733,000 after purchasing an additional 338 shares in the last quarter. Summit Investment Advisors Inc. raised its stake in BridgeBio Pharma by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 14,706 shares of the company's stock worth $404,000 after buying an additional 466 shares during the period. Steward Partners Investment Advisory LLC raised its stake in BridgeBio Pharma by 85.8% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company's stock worth $28,000 after buying an additional 472 shares during the period. Xponance Inc. raised its stake in BridgeBio Pharma by 9.1% during the 4th quarter. Xponance Inc. now owns 10,089 shares of the company's stock worth $277,000 after buying an additional 844 shares during the period. Finally, Tocqueville Asset Management L.P. raised its stake in BridgeBio Pharma by 7.2% during the 4th quarter. Tocqueville Asset Management L.P. now owns 18,975 shares of the company's stock worth $521,000 after buying an additional 1,275 shares during the period. Institutional investors and hedge funds own 99.85% of the company's stock.

Insider Buying and Selling at BridgeBio Pharma

In related news, CAO Maricel Apuli sold 1,026 shares of the stock in a transaction that occurred on Friday, May 2nd. The shares were sold at an average price of $38.51, for a total transaction of $39,511.26. Following the sale, the chief accounting officer now owns 147,639 shares in the company, valued at approximately $5,685,577.89. This trade represents a 0.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Genetic Disorder L.P. Kkr sold 6,000,000 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $32.96, for a total transaction of $197,760,000.00. Following the transaction, the insider now owns 19,260,971 shares of the company's stock, valued at approximately $634,841,604.16. This represents a 23.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 12,410,217 shares of company stock valued at $417,634,332 in the last quarter. Company insiders own 18.20% of the company's stock.

BridgeBio Pharma Stock Performance

BBIO traded up $0.10 on Friday, reaching $33.84. The company had a trading volume of 2,618,238 shares, compared to its average volume of 2,435,517. BridgeBio Pharma, Inc. has a fifty-two week low of $21.62 and a fifty-two week high of $39.54. The stock has a market cap of $6.43 billion, a P/E ratio of -11.87 and a beta of 1.15. The company's fifty day moving average is $34.40 and its 200 day moving average is $31.47.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The company reported ($0.88) EPS for the quarter, beating analysts' consensus estimates of ($1.00) by $0.12. The company had revenue of $36.74 million during the quarter, compared to analyst estimates of $57.14 million. The firm's quarterly revenue was down 44.8% on a year-over-year basis. During the same quarter last year, the company posted ($0.20) EPS. On average, sell-side analysts expect that BridgeBio Pharma, Inc. will post -3.67 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently commented on BBIO shares. Scotiabank raised their price objective on BridgeBio Pharma from $52.00 to $55.00 and gave the stock a "sector outperform" rating in a research note on Wednesday, April 30th. JPMorgan Chase & Co. raised their price objective on BridgeBio Pharma from $44.00 to $50.00 and gave the stock an "overweight" rating in a research note on Monday, March 24th. UBS Group raised their price objective on BridgeBio Pharma from $65.00 to $72.00 and gave the stock a "buy" rating in a research note on Wednesday, April 30th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $95.00 price objective on shares of BridgeBio Pharma in a research note on Friday, February 21st. Finally, Citigroup raised their price objective on BridgeBio Pharma from $45.00 to $49.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. One analyst has rated the stock with a hold rating and eleven have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $57.09.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.